ERBB2 and triple-negative breast carcinoma: Following the publication of landmark trials that showed the benefit of adapting the adjuvant treatment based on the response to neoadjuvant treatment, neoadjuvant chemotherapy had become the standard of care in selected patients with early-stage HER-2 overexpressed or triple negative breast cancer [38,39].